About Provesica
Provesica is a Cambridge-based biopharmaceutical company specialising in overactive bladder. The Company’s development compound, XEN-D0501, is highly potent antagonist of the vanilloid receptor, TRPV1, and is about to start Phase 2 clinical development.
In addition to XEN-D0501, Provesica owns a portfolio of intellectual property covering diverse TRPV1 antagonists suitable for development in overactive bladder or other indications where TRPV1 has been validated as an intervention target.
Provesica was established in 2010 following the demerger of the overactive bladder and TRPV1 interests of Xention Ltd, an ion channel specialist drug discovery and development company. Provesica has so far raised £4 million in finance to progress its lead programme through Phase 2 development.
- Focus : Manufacturer
- Industry : Pharma
